B · Normal
[Hengrui Medicine: Subsidiary’s innovative drug Fossilapapital and Plonosetron for Injection has been approved for new indications] On November 19th, Hengrui Medicine (600276.SH) announced that the company’s subsidiary Fujian Shengdi Medicine received a notice from the State Food and Drug Administration , approved the new indication of the company's independently developed Class 1 innovative drug, China's first ultra-long-acting original dual-target antiemetic injection Foslorapitampalonosetron for injection, for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy in adult patients. The drug has been approved for marketing in May 2025 and is used to prevent nausea and vomiting caused by highly emetogenic chemotherapy. Up to now, the cumulative R&D investment in related projects is approximately 260 million yuan.
A-share announcement express 🕐 2026-11-19 17:00

Related telegraphs

Comments

0/500
Captcha (click to refresh)
No comments yet